- Country: Russia
- Summary: Empagliflosin Drug to Ensure the Prevention of the Development of Cardiovascular Diseases and Cardiovascular Complications in High-Risk Patients Located at the Dispensary Nabble ...
- RUT Ref No: 121266887
- Deadline: 26 Jun 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: RUB 2058615.00
- Notice Type: Tender
- Document Ref. No.: 0168500000625002341
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Empagliflosin drug to ensure the prevention of the development of cardiovascular diseases and cardiovascular complications in high-risk patients located at the dispensary observation in 2025
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINEmpagliflosin Drug to Ensure the Prevention of the Development of Cardiovascular Diseases and Cardiovascular Complications in High-Risk Patients Located at the Dispensary Nabble ... - Russian Tender
The STATE PROCUREMENT AGENCY OF THE ULYANOVSK REGION, a Government sector organization in Russia, has announced a new tender for Empagliflosin Drug to Ensure the Prevention of the Development of Cardiovascular Diseases and Cardiovascular Complications in High-Risk Patients Located at the Dispensary Nabble .... This tender is published on RussianTenders under RUT Ref No: 121266887 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-06-26.
The estimated tender value is RUB 2058615.00, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
